SCHEMBL955853

SCHEMBL955853

CN(C)C=C1C(=O)CCCC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
POLB P06746 3/20 0.57
TP53 P04637 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MAP1LC3B Q9GZQ8 6/20 0.44
MAPT P10636 5/20 0.40
ALDH1A1 P00352 4/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
CREBBP Q92793 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HIF1A Q16665 1/20 0.40
GAA P10253 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3142596 0.95 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL21635879 0.93 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL6837311 0.90 MAP1LC3B (0.47) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL24933630 0.78 MAP1LC3B (0.43) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL1310728 0.78 SMN1; SMN2 (0.45) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL1310726 0.78 SMN1; SMN2 (0.45) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL12110722 0.78 SMN1; SMN2 (0.45) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL3588788 0.73 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL2727810 0.73 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1POLBTP53CTDSP1
SCHEMBL2727811 0.73 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1POLBTP53CTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4055016-B1 GPR52 MODULATOR COMPOUNDS NXERA PHARMA UK LTD (GB) 2026-04-29 EP disclosed
EP-4536655-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF Sionna Therapeutics Inc. (US) 2025-04-16 EP disclosed
CN-119677730-A Compounds, compositions, and methods of use thereof 希安纳医疗公司 2025-03-21 CN disclosed
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 CN disclosed
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 EP disclosed
CN-118598868-A GPR52 modulator compound 江苏海洋大学 2024-09-06 CN disclosed
WO-2023240267-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2023-12-14 WO disclosed
WO-2023240267-A2 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2023-12-14 WO disclosed
US-20230348401-A1 Inhibitors of Glucose-6-phosphate Dehydrogenase and Uses Thereof THE TRUSTEES OF PRINCETON UNIVERSITY 2023-11-02 US disclosed
US-20230348401-A1 Inhibitors of Glucose-6-phosphate Dehydrogenase and Uses Thereof THE TRUSTEES OF PRINCETON UNIVERSITY 2023-11-02 US disclosed
US-5068334-A Analgesics and antipyretics KARL THOMAE GMBH (DE) 1991-11-26 US disclosed
EP-0192783-B1 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1991-04-17 EP disclosed
EP-0276833-A2 Dipyrazoles useful as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-03 EP disclosed
EP-0276834-A1 Cycloalkane [1,2-c:4,3-c'] dipyrazoles MERRELL DOW PHARMACEUTICALS INC. (US) 1988-08-03 EP disclosed
US-4742165-A HERBICIDES MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-05-03 US disclosed
US-4734430-A Dipyrazoles and their use as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-03-29 US disclosed
US-4734429-A Cycloalkane[1,2-c:4,3-c']dipyrazoles and their use as bronchodilators MERRELL DOW PHARMACEUTICALS INC. (US) 1988-03-29 US disclosed
US-4734418-A Quinazoline compounds and antihypertensives MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-03-29 US disclosed
EP-0192783-A1 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1986-09-03 EP disclosed
EP-0188094-A2 Quinazoline derivatives and antihypertensive preparations containing same as effective components MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1986-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348401-A1 Inhibitors of Glucose-6-phosphate Dehydrogenase and Uses Thereof G6PD, UGDH, GPI SMN1; SMN2 4412/4885L3MBTL1 3320/4885POLB 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.